Works matching IS 03065251 AND DT 2006 AND VI 61 AND IP 4


Results: 17
    1
    2

    The phase 0 microdosing concept.

    Published in:
    British Journal of Clinical Pharmacology, 2006, v. 61, n. 4, p. 367, doi. 10.1111/j.1365-2125.2006.02575.x
    By:
    • Garner, R. Colin;
    • Lappin, Graham
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Monitoring for adverse drug reactions.

    Published in:
    British Journal of Clinical Pharmacology, 2006, v. 61, n. 4, p. 371, doi. 10.1111/j.1365-2125.2006.02596.x
    By:
    • Coleman, J. J.;
    • Ferner, R. E.;
    • Evans, S. J. W.
    Publication type:
    Article
    13
    14
    15

    Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

    Published in:
    British Journal of Clinical Pharmacology, 2006, v. 61, n. 4, p. 440, doi. 10.1111/j.1365-2125.2006.02599.x
    By:
    • Bernsdorf, Annika;
    • Giessmann, Thomas;
    • Modess, Christiane;
    • Wegner, Danilo;
    • Igelbrink, Stefanie;
    • Hecker, Ute;
    • Haenisch, Sierk;
    • Cascorbi, Ingolf;
    • Terhaag, Bernd;
    • Siegmund, Werner
    Publication type:
    Article
    17